Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib and Trametinib in BRAF V600E NSCLC
NCT01336634Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2011
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label trial of dabrafenib + trametinib and trametinib in non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by Novartis. Primary endpoint: Overall Response Rate at 50 months. Started Aug 2011; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01336634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01336634.